NASDAQ$RNA

Atrium Therapeutics Inc · Q2 2022 earnings

Q2 2022 earnings ·

Headline financials

Total Revenue

$2.18M

Previous: $2.61M-16.5%
EPS

-$0.92

No prior period
Capital Expenditures

-$2.08M

Previous: -$1.23M-68.7%
Free Cash Flow

-$47.8M

Previous: -$27.6M-73.2%
Net Income

-$45.7M

Previous: -$26.4M-73.4%
Operating Income

-$46.3M

Previous: -$26.4M-75.6%
Gross Profit

$0.00

Previous: $0.00

Revenue & EPS history

Atrium Therapeutics Inc · Revenue · Quarterly

$2.18M

Q2 2022-16.5%vs Q2 2021
Beat estimate in 1 of 1 quarters(100%)
ActualEstimate

Revenue by segment

Atrium Therapeutics Inc · $19.6M total across 1 segment · Q1 2026

  • Reportable Segment
    $19.6M—

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro